Imaging Core
Imaging Core
批准号:
8764764
负责人:
Henry Charles Manning
金额:
$12.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2018-08-31
关键词:
AddressAnimalsApoptosisBasic ScienceBiological AssayBiological MarkersBiological ProcessBiologyBreastBreast Cancer TreatmentCancer CenterChemistryClinicalClinical Drug DevelopmentClinical SciencesClinical TrialsCollaborationsDataDevelopmentDiagnosisDrug TargetingEngineeringEquipmentFacultyFluorescenceFosteringFundingGoalsGrantHistologyHousingHuman ResourcesImageImage AnalysisImaging TechniquesIn SituInflammationInstitutesInstructionLaboratoriesMagnetic ResonanceMagnetic Resonance ImagingMammary NeoplasmsMedicineMetabolismMethodsMetricMissionMolecularMonitorPatient CarePhilosophyPhysicsPilot ProjectsPlayPositron-Emission TomographyPreparationProtocols documentationResearchResearch PersonnelResearch SupportResource DevelopmentResourcesRoentgen RaysRoleScienceServicesTechniquesTissuesTranslational ResearchTranslationsUltrasonographyUniversitiesX-Ray Computed Tomographyangiogenesisanticancer researchassay developmentbasebioimagingcancer initiationcancer therapycost effectivedrug distributionforgingimaging modalityin vivoinnovationinstrumentmalignant breast neoplasmmolecular imagingmolecular/cellular imagingnon-invasive imagingnovelpre-clinicalreceptor expressionresponsesingle photon emission computed tomographytooltreatment responsetumor initiation
中文摘要
成像核心的总体目标是开发、优化、实施和验证定量、替代
预测性生物标志物:1)药物靶点接合,2)由特定靶点诱导的抗肿瘤作用的类型,
治疗,和3)乳腺癌对治疗的反应。成像核心将提供全方位的小型
动物功能、解剖和分子成像技术,包括磁共振、计算机
断层扫描、超声、荧光、单光子发射计算机断层扫描(SPECT)和正电子
发射断层扫描(PET)成像。Breast SPORE研究人员还将获得新型探头
开发资源,包括高通量、面向多样性的合成能力,适用于
鉴定新的成像化合物,以及最先进的范德比尔特大学的资源
放射化学研究中心。将提供新的和建立的分子成像技术,
专门定制用于评估细胞代谢和增殖,凋亡,
血管生成、受体表达和炎症。与上一个融资周期一样,成像核心将
继续与SPORE中的其他核心合作,并与VUIIS建立新的联系,
服务具有很高的成本效益。为了向项目提供这种支持,成像核心已经确定了
以下三个具体的施舍:
1.促进先进的定量非侵入性成像和乳腺癌专家之间的合作
癌症研究。特别是,核心将支持所有主要成像模式的专家,
特别强调正电子发射断层扫描(PET)和磁共振成像(MRI)。
2.开发、验证和提供药物分布、药物靶点的非侵入性成像指标
乳腺孢子研究者的参与、肿瘤发生、进展和治疗反应。
3.为定量成像数据分析、定制成像开发提供支持
协议,包括多种成像模式、组织学和
其他原位测定和新的成像生物标志物的开发。
英文摘要
The overall goal of the Imaging Core is to develop, optimize, implement, and validate quantitative, surrogate
predictive biomarkers of: 1) drug target engagement, 2) the type of antitumor effect induced by a particular
treatment, and 3) the response of breast cancer to treatment. The Imaging Core will offer a full range of small
animal functional, anatomical, and molecular imaging techniques, including magnetic resonance, computed
tomography, ultrasound, fluorescence, single photon emission computed tomography (SPECT) and positron
emission tomography (PET) imaging. Breast SPORE investigators will also have access to novel probe
development resources, including high-throughput, diversity-oriented synthesis capabilities suitable for
identifying novel imaging compounds, as well as the resources of the state-of-the-art Vanderbilt University
Research Radiochemlstry Core. Novel and established molecular imaging techniques will be offered which are
specifically tailored for assessing quantitative metrics of cellular metabolism and proliferation, apoptosis,
angiogenesis, receptor expression and inflammation. As in the previous funding cycle, the Imaging Core will
continue to partner with other Cores in the SPORE and forge new connections with the VUIIS such that
services are highly cost-effective. To provide this support to the projects, the Imaging Core has identified the
following three specific alms:
1. Foster collaborations between experts in advanced, quantitative non-invasive imaging and breast
cancer research. In particular, the Core will support experts in all major imaging modalities, with
particular emphasis on positron emission tomography (PET) and magnetic resonance imaging (MRI).
2. Develop, validate, and provide non-invasive imaging metrics of drug distribution, drug target
engagement, tumor initiation, progression and treatment response for Breast SPORE investigators.
3. Provide support for analysis of quantitative imaging data, development of customized imaging
protocols, including the co-registration and integration of multiple imaging modalities, histology and
other in situ assays, and the development of novel imaging biomarkers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Quantitative Imaging of OXPHOS in Pancreatic Cancer
-
批准号:10649885
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2023
-
负责人:Henry Charles Manning
-
依托单位:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
-
批准号:9890526
-
项目类别:
-
资助金额:$58.58万
-
财政年份:2020
-
负责人:Henry Charles Manning
-
依托单位:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
-
批准号:10687038
-
项目类别:
-
资助金额:$57.72万
-
财政年份:2020
-
负责人:Henry Charles Manning
-
依托单位:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
-
批准号:10267667
-
项目类别:
-
资助金额:$58.74万
-
财政年份:2020
-
负责人:Henry Charles Manning
-
依托单位:
Core 2: Mouse and Human Molecular Imaging
-
批准号:10443609
-
项目类别:
-
资助金额:$24.23万
-
财政年份:2019
-
负责人:Henry Charles Manning
-
依托单位:
Core 2: Mouse and Human Molecular Imaging
-
批准号:10700844
-
项目类别:
-
资助金额:$24.23万
-
财政年份:2019
-
负责人:Henry Charles Manning
-
依托单位:
Core 2: Mouse and Human Molecular Imaging
-
批准号:10218107
-
项目类别:
-
资助金额:$24.1万
-
财政年份:2019
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:9085233
-
项目类别:
-
资助金额:$45.27万
-
财政年份:2016
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:9248709
-
项目类别:
-
资助金额:$17.89万
-
财政年份:2016
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:8881115
-
项目类别:
-
资助金额:$27.39万
-
财政年份:2012
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:8371615
-
项目类别:
-
资助金额:$45.27万
-
财政年份:2012
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:8529474
-
项目类别:
-
资助金额:$42.56万
-
财政年份:2012
-
负责人:Henry Charles Manning
-
依托单位:
Dedicated Quantitative Fluorescence Tomography System for Small Animal Imaging
-
批准号:7794463
-
项目类别:
-
资助金额:$35.06万
-
财政年份:2010
-
负责人:Henry Charles Manning
-
依托单位:
Biological Basis of Imaging Biomarkers in Colorectal Cancer
-
批准号:8494590
-
项目类别:
-
资助金额:$28.85万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Molecular Determinants Affecting FLT-PET in Colorectal Cancer
-
批准号:7944026
-
项目类别:
-
资助金额:$49.86万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Biological Basis of Imaging Biomarkers in Colorectal Cancer
-
批准号:7699155
-
项目类别:
-
资助金额:$31.8万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Biological Basis of Imaging Biomarkers in Colorectal Cancer
-
批准号:8192915
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Molecular Determinants Affecting FLT-PET in Colorectal Cancer
-
批准号:7816526
-
项目类别:
-
资助金额:$49.96万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Biological Basis of Imaging Biomarkers in Colorectal Cancer
-
批准号:8305039
-
项目类别:
-
资助金额:$30.7万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Synergizing Quantitative HTS Technologies to Guide MIA Discovery and Development
-
批准号:8042612
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2008
-
负责人:Henry Charles Manning
-
依托单位:
海外基金